💊 **Glenmark's U.S. Arm Launches Methylene Blue Injection in the U.S. Market**

📅 **June 17, 2026** Glenmark Pharmaceuticals Inc., USA**, a subsidiary of **Glenmark Pharmaceuticals Ltd.**, has announced the launch of **Methylene Blue Injection USP, 50 mg/10 mL (5 mg/mL) Single-Dose Vial** in the United States. 🔹 Key Highlights: ✅ The product is **bioequivalent and therapeutically equivalent** to the reference drug **ProvayBlue® Injection** of Provepharm SAS. ✅ According to IQVIA data, the reference product's market generated approximately **US$19 million in annual sales** for the 12-month period ended April 2026. ✅ The launch strengthens Glenmark's presence in the U.S. institutional market and expands its injectable portfolio. 💬 **Marc Kikuchi, President & Business Head – North America, said:** > "The launch of Methylene Blue Injection USP reflects Glenmark's ongoing commitment to expanding access to quality, affordable medicines for healthcare institutions and the patients they serve." ### 📌 Why It Matters for Investors: * Expands Glenmark's U.S. injectable business. * Targets an established niche market with meaningful revenue potential. * Reinforces the company's strategy of growing its institutional and generic portfolio in North America. 👍 Like, Share & Follow **AFS Trading Edge** for more market and corporate updates. *Disclaimer: This post is for educational and informational purposes only and should not be construed as investment advice.* $GLENMARK